2010
High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010, 10: 186. PMID: 20459695, PMCID: PMC2875218, DOI: 10.1186/1471-2407-10-186.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBiomarkers, TumorCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell DifferentiationCohort StudiesConnecticutFemaleGreeceHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm StagingPredictive Value of TestsProportional Hazards ModelsProto-Oncogene Proteins c-bcl-2Reproducibility of ResultsRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUp-RegulationConceptsNon-small cell lung cancer patientsCell lung cancer patientsNon-squamous tumorsLung cancer patientsBcl-2 expressionNSCLC patientsCancer patientsBcl-2Favorable outcomeIndependent cohortSmall cell lung cancer patientsIndependent lower riskNon-squamous histologySubgroup of patientsHigh expressersSquamous cell carcinomaHigh Bcl-2 expressionBcl-2 protein levelsSquamous histologyMedian survivalPrognostic factorsValidation cohortCell carcinomaPathological characteristicsPrognostic stratification
2007
Treatment of Lung Cancer in Older Patients
Tanoue LT, Gettinger S. Treatment of Lung Cancer in Older Patients. Clinics In Chest Medicine 2007, 28: 735-749. PMID: 17967291, DOI: 10.1016/j.ccm.2007.08.003.Peer-Reviewed Original Research
2006
Evaluation and definitive management of medically inoperable early stage non-small-cell lung cancer. Part 2: newer treatment modalities.
Decker RH, Tanoue LT, Colasanto JM, Detterbeck FC, Wilson LD. Evaluation and definitive management of medically inoperable early stage non-small-cell lung cancer. Part 2: newer treatment modalities. Oncology 2006, 20: 899-905; discussion 905-8, 913. PMID: 16922260.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerPoor baseline pulmonary functionCurative treatment alternativeInoperable early stageSingle-modality radiotherapyComorbid medical illnessesBaseline pulmonary functionBetter overall survivalMinority of patientsRadiotherapy dose escalationDefinitive treatment optionEarly-stage patientsOverall survival dataNew treatment modalitiesMediastinal nodalAdvanced diseaseCurative resectionDistant failureOverall survivalPulmonary functionDose escalationDefinitive managementMedical illnessCancer mortalityEvaluation and definitive management of medically inoperable early-stage non-small-cell lung cancer. Part 1: Assessment and conventional radiotherapy.
Decker RH, Tanoue LT, Colasanto JM, Detterbeck FC, Wilson LD. Evaluation and definitive management of medically inoperable early-stage non-small-cell lung cancer. Part 1: Assessment and conventional radiotherapy. Oncology 2006, 20: 727-36. PMID: 16841796.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerPoor baseline pulmonary functionCurative treatment alternativeSingle-modality radiotherapyComorbid medical illnessesBaseline pulmonary functionBetter overall survivalEarly-stage patientsMinority of patientsRadiotherapy dose escalationDefinitive treatment optionOverall survival dataMediastinal nodalAdvanced diseaseCurative resectionDistant failureOverall survivalPulmonary functionDose escalationDefinitive managementMedical illnessCancer mortalityTreatment optionsRadiofrequency ablation